Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Clinical Trial Optional)" aimed at promoting innovative clinical research in the treatment of Substance Use Disorders (SUD). This initiative seeks applications that explore and validate novel targets for non-invasive brain stimulation (NIBS) and assess their neurobiological, cognitive, and behavioral impacts, potentially leading to significant advancements in SUD treatment methodologies. The program allows for up to five years of funding, with a total allocation of up to $1.5 million across fiscal years 2024 to 2026, and encourages diverse research perspectives through a required Plan for Enhancing Diverse Perspectives (PEDP). Interested applicants should note that the submission window opens on December 16, 2023, with a final due date of August 14, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.